subject area of
- Addendum to Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes: 2015 Interim Update Academic Article
- CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis Academic Article
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum Academic Article
- Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data Academic Article
- Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice Academic Article
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial Academic Article
- Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors Academic Article
- Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis Academic Article
- Management of mitochondrial diabetes in the era of novel therapies Academic Article
- Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials Academic Article
- Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes–2015 Interim Update Academic Article
- Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses Academic Article
- Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Academic Article
- Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials Academic Article
- Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure Academic Article
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels Academic Article
- The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice Academic Article
- Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study Academic Article
- Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review Academic Article